Current Treatment Options in Psychiatry

, Volume 5, Issue 1, pp 162–181 | Cite as

Novel Therapeutics in Bipolar Disorder

  • Sabrina C. da Costa
  • Rodrigo Machado-Vieira
  • Jair C. Soares
Bipolar and Other Mood Disorders (B Goldstein and D Hafeman, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Bipolar and Other Mood Disorders

Opinion statement

Recent findings

Existing pharmacological treatments for bipolar disorder have demonstrated insufficient efficacy, delayed onset of action, and significant side effects. Emerging evidence suggest that rapid antidepressant activity can be achieved in humans, and findings from the use of glutamatergic and anticholinergic drugs, for instance, reveal promising results.

Purpose of review

In the present article, we review evidence supporting the use of novel therapies in bipolar disorder, with focus on drugs acting in the glutamatergic system. In addition, anticholinergic drugs, melatonergic agonists, glucocorticoid modulators, and mechanistically diverse anti-inflammatory agents will be briefly discussed.

Summary

While preliminary findings on novel therapies for bipolar disorder are encouraging, current evidence is still insufficient to support extensive use of these drugs routinely. Long-term safety, tolerability, and efficacy remain unclear; several clinical trials are underway and may add clarity to these questions. Early detection and prompt intervention have the potential to decelerate illness progression and lessen the burden associated with bipolar disorder; thus, novel therapies with rapid and sustained clinical benefits are urgent.

Keywords

Bipolar disorder Glutamatergic system Cholinergic system Melatonergic system HPA-axis Immune dysregulation and oxidative stress 

Notes

Compliance with ethical standards

Conflicts of Interest

Sabrina C. da Costa, Rodrigo Machado-Vieira, and Jair C. Soares declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article is a review paper. Although it alludes to clinical and preclinical work, it does not contain any studies with human or animal subjects performed by any of the authors in this section.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance: Compelling evidence from clinical trials, systematic reviews and meta-analyses.

  1. 1.
    Merikangas KR, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543–52.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Mathers CD, Iburg KM, Begg S. Adjusting for dependent comorbidity in the calculation of healthy life expectancy. Popul Health Metr. 2006;4:4.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Whiteford HA, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1575–86.PubMedCrossRefGoogle Scholar
  4. 4.
    Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry. 1995;152:1635–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Frye MA, et al. Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar i maintenance studies. Acta Psychiatr Scand. 2009;120:10–3.PubMedCrossRefGoogle Scholar
  6. 6.
    McAllister-Williams RH. Relapse prevention in bipolar disorder: a critical review of current guidelines. J Psychopharmacol. 2006;20:12–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Perlis RH, et al. Predictors of recurrence in bipolar disorder: primary program for bipolar disorder (STEP-BD). Am J Psychiatry. 2006;163:217–24.PubMedCrossRefGoogle Scholar
  8. 8.
    Judd LL, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Judd LL, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Wells BE, et al. Correlates of concurrent energy drink and alcohol use among socially active adults. Am J Drug Alcohol Abuse. 2013;39:8–15.PubMedCrossRefGoogle Scholar
  11. 11.
    Goodwin GM. Bipolar depression and treatment with antidepressants. Br J Psychiatry. 2012;200:5–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Saunders KEA, Goodwin GM. New approaches in the treatment of bipolar depression. Curr Top Behav Neurosci. 2013;14:291–307.PubMedCrossRefGoogle Scholar
  13. 13.
    Tondo L, Vázquez GH, Baldessarini RJ. Options for pharmacological treatment of refractory bipolar depression. Curr Psychiatry Rep. 2014;16:431.PubMedCrossRefGoogle Scholar
  14. 14.
    • Sienaert P, Lambrichts L, Dols A, De Fruyt J. Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review. Bipolar Disord. 2013;15:61–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013;70:931–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Nordentoft M, Mortensen PB, Pedersen CB. Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry. 2011;68:1058–64.PubMedCrossRefGoogle Scholar
  17. 17.
    Poon SH, Sim K, Sum MY, Kuswanto CN, Baldessarini RJ. Evidence-based options for treatment-resistant adult bipolar disorder patients. Bipolar Disord. 2012;14:573–84.PubMedCrossRefGoogle Scholar
  18. 18.
    M M, C H. Treatment-resistant bipolar depression (TRBD): definition and therapeutic strategies. Bipolar Disord. 2012;14:101–2.Google Scholar
  19. 19.
    Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O’Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, B M. Canadian Network for mood and anxiety treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;1–44.Google Scholar
  20. 20.
    Bowden CL, Gitlin MJ, Keck PE, Suppes T & Ph D. Treatment of patients with bipolar disorder second edition. APA Pratice Guidelines; 2010. pp. 1–82.  https://doi.org/10.1176/appi.books.9780890423363.50051
  21. 21.
    Rybakowski JK. Factors associated with lithium efficacy in bipolar disorder. Harv Rev Psychiatry. 2014;22:353–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Berghöfer A, et al. Stability of lithium treatment in bipolar disorder—long-term follow-up of 346 patients. Int J Bipolar Disord. 2013;1:11.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Sachs GS, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711–22.PubMedCrossRefGoogle Scholar
  24. 24.
    Loebel A et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled Study. Am J Psychiatry. 2013;1–9.  https://doi.org/10.1176/appi.ajp.2013.13070984
  25. 25.
    Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar i depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2014;155:20–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Woo YS, Wang HR, Bahk WM. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:1521–9.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Yatham LN, et al. Canadian network for mood and anxiety treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7(Suppl 3):5–69.PubMedCrossRefGoogle Scholar
  28. 28.
    Thase ME, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs. 2012;26:435–60.PubMedCrossRefGoogle Scholar
  30. 30.
    Derry S, Moore RA. Atypical antipsychotics in bipolar disorder: systematic review of randomized trials. BMC Psychiatry. 2007;7:40.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Machado-Vieira R, Henter ID, Manji HK & Zarate CA. Potential novel treatments in bipolar depression. Milestones Drug Ther. 2016;259–285.  https://doi.org/10.1007/978-3-319-31,689-5_12
  32. 32.
    Iadarola ND, et al. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015;6:97–114.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Niciu MJ et al. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry. 2014;75.Google Scholar
  34. 34.
    Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7:426–37.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Henter ID et al. Mood therapeutics: novel pharmacological approaches for treating depression. Exp Rev Clin Pharmacol. 2016.Google Scholar
  36. 36.
    Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth. 1996;77:441–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Berman RM, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–4.PubMedCrossRefGoogle Scholar
  38. 38.
    • Zarate CA, et al. A Randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856.Google Scholar
  39. 39.
    • Murrough JW, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134–42.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    • Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord. 2015;17:438–43.PubMedCrossRefGoogle Scholar
  41. 41.
    • Zarate CA, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939–46.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    • Diazgranados N, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793–802.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    • Kantrowitz JT, Halberstam B, Gangwisch J. Single-dose ketamine followed by daily D-cycloserine in treatment-resistant bipolar depression. J Clin Psychiatry. 2015;76:737–8.PubMedCrossRefGoogle Scholar
  44. 44.
    • Caddy C, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev. 2015;9:CD011612.Google Scholar
  45. 45.
    Kraus C, et al. Administration of ketamine for unipolar and bipolar depression. Int J Psychiatry Clin Pract. 2017;21:2–12.PubMedCrossRefGoogle Scholar
  46. 46.
    • Vande Voort JL, et al. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord. 2016;206:300–4.PubMedCrossRefGoogle Scholar
  47. 47.
    • Murrough JW, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45:3571–80.PubMedCrossRefGoogle Scholar
  48. 48.
    • Diamond PR, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 2014;28:536–44.PubMedCrossRefGoogle Scholar
  49. 49.
    • Rasmussen KG, et al. Serial infusions of low-dose ketamine for major depression. J. Psychopharmacol. 2013;27:444–50.PubMedCrossRefGoogle Scholar
  50. 50.
    van het Rot M, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139–45.CrossRefGoogle Scholar
  51. 51.
    Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47:S233–41.PubMedCrossRefGoogle Scholar
  52. 52.
    Mizuta I, et al. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett. 2001;310:117–20.PubMedCrossRefGoogle Scholar
  53. 53.
    • Brennan BP, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology. 2010;35:834–46.PubMedCrossRefGoogle Scholar
  54. 54.
    • Zarate CA, et al. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry. 2005;57:430–2.PubMedCrossRefGoogle Scholar
  55. 55.
    • Park LT et al. A double-blind, placebo-controlled, pilot study of riluzole monotherapy for acute bipolar depression. J Clin Psychopharmacol. 2017;1.  https://doi.org/10.1097/JCP.0000000000000693.
  56. 56.
    • Serra G, et al. Three-year, naturalistic, mirror-image assessment of adding memantine to the treatment of 30 treatment-resistant patients with bipolar disorder. J Clin Psychiatry. 2015;76:e91–7.PubMedCrossRefGoogle Scholar
  57. 57.
    • Koukopoulos A, Koukopoulos AE, Reginaldi D, Serra G, Serra G. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord. 2012;136:163–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Sahraian A, Jahromi LR, Ghanizadeh A, Mowla A. Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol. 2017;37:246–9.PubMedCrossRefGoogle Scholar
  59. 59.
    • Zarate CA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163:153–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Anand A, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: A double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2012;14:64–70.PubMedCrossRefGoogle Scholar
  61. 61.
    Stevens J, Bies RR, Shekhar A, Anand A. Bayesian model of Hamilton Depression Rating Score (HDRS) with memantine augmentation in bipolar depression. Br J Clin Pharmacol. 2013;75:791–8.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Lee S-Y, et al. The effects of add-on low-dose memantine on cytokine levels in bipolar II depression. J Clin Psychopharmacol. 2014;34:337–43.PubMedCrossRefGoogle Scholar
  63. 63.
    Kishi T, Matsunaga S, Iwata N. A meta-analysis of memantine for depression. J Alzheimer’s Dis. 2017;57:113–21.CrossRefGoogle Scholar
  64. 64.
    Ahmed A, Simmons Z. Pseudobulbar affect: prevalence and management. Ther Clin Risk Manag. 2013;9:483–9.PubMedPubMedCentralGoogle Scholar
  65. 65.
    • Kelly TF, Lieberman DZ. The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS. J Affect Disord. 2014;167:333–5.PubMedCrossRefGoogle Scholar
  66. 66.
    • Chen SL, et al. Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder. Eur Neuropsychopharmacol. 2014;24:1753–9.PubMedCrossRefGoogle Scholar
  67. 67.
    • Lee S-Y, et al. The COMT Val158Met Polymorphism is associated with response to add-on dextromethorphan treatment in bipolar disorder. J Clin Psychopharmacol. 2017;37:94–8.PubMedCrossRefGoogle Scholar
  68. 68.
    • Heresco-Levy U, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol. 2013;16:501–6.PubMedCrossRefGoogle Scholar
  69. 69.
    • Nagele P, et al. Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial. Biol Psychiatry. 2015;78:10–8.PubMedCrossRefGoogle Scholar
  70. 70.
    • de Sousa RT, et al. Lithium increases nitric oxide levels in subjects with bipolar disorder during depressive episodes. J Psychiatr Res. 2014;55:96–100.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    • Moskal JR, et al. The development of rapastinel (formerly GLYX-13); a rapid acting and long lasting antidepressant. Curr Neuropharmacol. 2017;15:47–56.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Rajagopal L, Burgdorf JS, Moskal JR, Meltzer HY. GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice. Behav Brain Res. 2016;299:105–10.PubMedCrossRefGoogle Scholar
  73. 73.
    Burgdorf J, et al. Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats. Behav Brain Res. 2015;294:177–85.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    • Burgdorf J, et al. The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience. 2015;308:202–11.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    • Preskorn S, et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 2015;21:140–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Newport DJ, et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172:950–66.PubMedCrossRefGoogle Scholar
  77. 77.
    • Huang CC, et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry. 2013;74:734–41.PubMedCrossRefGoogle Scholar
  78. 78.
    • Zarate CA, et al. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry. 2013;74:257–64.PubMedCrossRefGoogle Scholar
  79. 79.
    • G S, MA S, S P, H-L S, D M. Adjunctive AZD6765, a low-trapping nmda channel blocker, in treatment-resistant major depressive disorder: a randomized, placebo-controlled study. Neuropsychopharmacology. 2012;38:S211–2.Google Scholar
  80. 80.
    • Sanacora G, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014;19:978–85.PubMedCrossRefGoogle Scholar
  81. 81.
    • Sanacora G, et al. Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, placebo-controlled study. Neuropsychopharmacology. 2017;42:844–53.PubMedCrossRefGoogle Scholar
  82. 82.
    Preskorn SH, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28:631–7.PubMedCrossRefGoogle Scholar
  83. 83.
    • Ibrahim L, et al. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012;32:551–7.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Janowsky DS, Davis JM, El-Yousef MK, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet. 1972;300:632–5.CrossRefGoogle Scholar
  85. 85.
    Bymaster FP, Felder CC. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Mol. Psychiatry. 2002;7(Suppl 1):S57–63.PubMedCrossRefGoogle Scholar
  86. 86.
    Carroll B, Frazer A, Schless A, Mendels J. Cholinergic reversal of manic symptoms. Lancet. 1973;301:427–8.CrossRefGoogle Scholar
  87. 87.
    • Gillin JC, et al. No antidepressant effect of biperiden compared with placebo in depression: a double-blind 6-week clinical trial. Psychiatry Res. 1995;58:99–105.PubMedCrossRefGoogle Scholar
  88. 88.
    Kasper S, Moises HW, Beckmann H. The anticholinergic biperiden in depressive disorders. Pharmacopsychiatria. 1981;14:195–8.PubMedCrossRefGoogle Scholar
  89. 89.
    • Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine. Arch Gen Psychiatry. 2006;63:1121.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    • Drevets WC, Furey ML. Replication of scopolamine’s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010;67:432–8.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Furey ML, Khanna A, Hoffman EM, Drevets WC. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology. 2010;35:2479–88.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    • Furey ML, Zarate CA. Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side effects. J Clin Psychiatry. 2013;74:850–1.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Jaffe RJ, Novakovik V, Peselow ED. Scopolamine as an antidepressant: a systematic review. Clin Neuropharmacol. 2013;36:24–6.PubMedCrossRefGoogle Scholar
  94. 94.
    Drevets WC, Zarate CA, Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: A review. Biol Psychiatry. 2013;73:1156–63.PubMedCrossRefGoogle Scholar
  95. 95.
    Pacchierotti C, Iapichino S, Bossini L, Pieraccini F, Castrogiovanni P. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol. 2001;22:18–32.PubMedCrossRefGoogle Scholar
  96. 96.
    Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol. 2004;25:177–95.PubMedCrossRefGoogle Scholar
  97. 97.
    Brown GM. Melatonin in psychiatric and sleep disorders: therapeutic implications. CNS Drugs. 1995;3:209–26.CrossRefGoogle Scholar
  98. 98.
    • Fornaro M, et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatr Dis Treat. 2013;9:243–51.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    • Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord. 2007;9:628–35.PubMedCrossRefGoogle Scholar
  100. 100.
    Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:g1888.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C. Agomelatine efficacy and acceptability revisited: Systematic review and meta-analysis of published and unpublished randomized trials. Br J Psychiatry. 2013;203:179–87.PubMedCrossRefGoogle Scholar
  102. 102.
    • Yatham LN, et al. Agomelatine or placebo as adjunctive therapy to a mood stabilizer in bipolar I depression: randomized double-blind placebo-controlled trial. Br J Psychiatry. 2016;208:78–86.PubMedCrossRefGoogle Scholar
  103. 103.
    Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008;213:93–118.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Pace TWW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun. 2007;21:9–19.PubMedCrossRefGoogle Scholar
  105. 105.
    Marx CE, et al. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology. 2006;31:1249–63.PubMedCrossRefGoogle Scholar
  106. 106.
    Carroll BJ, et al. Pathophysiology of hypercortisolism in depression: pituitary and adrenal responses to low glucocorticoid feedback. Acta Psychiatr Scand. 2012;125:478–91.PubMedCrossRefGoogle Scholar
  107. 107.
    • Belanoff JK, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002;52:386–92.PubMedCrossRefGoogle Scholar
  108. 108.
    DeBattista C. Augmentation and combination strategies for depression. J Psychopharmacol. 2006;20:11–8.PubMedCrossRefGoogle Scholar
  109. 109.
    • DeBattista C, et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry. 2006;60:1343–9.PubMedCrossRefGoogle Scholar
  110. 110.
    • Brown ES, et al. A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression. Neuropsychopharmacology. 2014;39:2867–73.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    • Wolkowitz OM, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry. 1999;156:646–9.PubMedGoogle Scholar
  112. 112.
    Brown ES, Bobadilla L, Rush AJ. Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review. Bipolar Disord. 2001;3:23–9.PubMedCrossRefGoogle Scholar
  113. 113.
    • Wolkowitz OM, et al. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry. 1999;45:1070–4.PubMedCrossRefGoogle Scholar
  114. 114.
    • Sigalas PD, Garg H, Watson S, McAllister-Williams RH, Ferrier IN. Metyrapone in treatment-resistant depression. The. Adv Psychopharmacol. 2012;2:139–49.CrossRefGoogle Scholar
  115. 115.
    • Ferrier IN, et al. Randomized controlled trial of antiglucocorticoid augmentation (metyrapone) of antidepressants in depression (ADD Study). Effic Mech Eval. 2015;2:1–98.CrossRefGoogle Scholar
  116. 116.
    • Jahn H, et al. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry. 2004;61:1235–44.PubMedCrossRefGoogle Scholar
  117. 117.
    • Gallagher P. et al. Antiglucocorticoid treatments for mood disorders. Cochrane Database Syst Rev. 2008;2–5.  https://doi.org/10.1002/14651858.CD005168.pub2.
  118. 118.
    Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74:15–25.PubMedCrossRefGoogle Scholar
  119. 119.
    Gold PW, Machado-Vieira R, Pavlatou MG. Clinical and biochemical manifestations of depression: relation to the neurobiology of stress. Neural Plasticity. 2015;2015:581976.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression. N Engl J Med. 1988;319:348–53.PubMedCrossRefGoogle Scholar
  121. 121.
    Frey BN, et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry. 2013;47:321–32.PubMedCrossRefGoogle Scholar
  122. 122.
    Schneider MR, DelBello MP, McNamara RK, Strakowski SM, Adler CM. Neuroprogression in bipolar disorder. Bipolar Disord. 2012;14:356–74.PubMedCrossRefGoogle Scholar
  123. 123.
    Rosenblat JD, et al. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord. 2016;18:89–101.PubMedCrossRefGoogle Scholar
  124. 124.
    Rosenblat JD, Gregory JM, McIntyre RS. Pharmacologic implications of inflammatory comorbidity in bipolar disorder. Curr Opin Pharmacol. 2016;29:63–9.PubMedCrossRefGoogle Scholar
  125. 125.
    • Nery FG, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23:87–94.PubMedCrossRefGoogle Scholar
  126. 126.
    Faridhosseini F, Sadeghi R, Farid L, Pourgholami M. Celecoxib: A new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol. 2014;29:216–23.PubMedCrossRefGoogle Scholar
  127. 127.
    Ayorech Z, Tracy DK, Baumeister D, Giaroli G. Taking the fuel out of the fire: Evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. J Affect Disord. 2015;174:467–78.PubMedCrossRefGoogle Scholar
  128. 128.
    • Arabzadeh S, et al. Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. Bipolar Disord. 2015;17:606–14.PubMedCrossRefGoogle Scholar
  129. 129.
    Fernandes BS, Dean OM, Dodd S, Malhi GS, Berk M. N-acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry. 2016;77:e457–66.PubMedCrossRefGoogle Scholar
  130. 130.
    Stolk P, et al. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids. 2010;82:9–14.PubMedCrossRefGoogle Scholar
  131. 131.
    • Soczynska JK, et al. A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar Disord. 2017;19:198–213.PubMedCrossRefGoogle Scholar
  132. 132.
    • Raison CL, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiat. 2013;70:31–41.CrossRefGoogle Scholar
  133. 133.
    • Toniolo RA, Fernandes FBF, Silva M, da Dias RS, Lafer B. Cognitive effects of creatine monohydrate adjunctive therapy in patients with bipolar depression: results from a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2016;  https://doi.org/10.1016/j.jad.2016.11.029.
  134. 134.
    McIntyre RS, et al. Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opin Pharmacother. 2006;7:1305–21.PubMedCrossRefGoogle Scholar
  135. 135.
    Hu Y, et al. Pioglitazone is an effective treatment for patients with post-stroke depression combined with type 2 diabetes mellitus. Exp Ther Med. 2015;10:1109–14.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    • Lin KW, Wroolie TE, Robakis T, Rasgon NL. Adjuvant pioglitazone for unremitted depression: clinical correlates of treatment response. Psychiatry Res. 2015;230:846–52.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    • Zeinoddini A, et al. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2015;32:167–73.PubMedCrossRefGoogle Scholar
  138. 138.
    • Roohafza H, Shokouh P, Sadeghi M, Alikhassy Z, Sarrafzadegan N. A possible role for pioglitazone in the management of depressive symptoms in metabolic syndrome patients (EPICAMP Study): a double blind, randomized clinical trial. Int Sch Res Not. 2014;2014:1–9.CrossRefGoogle Scholar
  139. 139.
    • Kemp DE, et al. PPAR-?? agonism as a modulator of mood: Proof-of-concept for pioglitazone in bipolar depression. CNS Drugs. 2014;28:571–81.PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    Kemp DE, Ismail-Beigi F, Calabrese JR. Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. Am J Psychiatry. 2009;166:619.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Kashani L, et al. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology. 2013;38:767–76.PubMedCrossRefGoogle Scholar
  142. 142.
    Colle R, et al. Pioglitazone could induce remission in major depression: a meta-analysis. Neuropsychiatr Dis Treat. 2017;13:9–16.PubMedCrossRefGoogle Scholar
  143. 143.
    Li X-B et al. Erythropoietin for cognitive deficits associated with schizophrenia, bipolar disorder, and major depression: a systematic review. Pharmacopsychiatry. 2017.  https://doi.org/10.1055/s-0043-114,670
  144. 144.
    Miskowiak KW, John Rush A, Gerds TA, Vinberg M, Kessing LV. Targeting treatments to improve cognitive function in mood disorder: suggestions from trials using erythropoietin. J Clin Psychiatry. 2016;77:e1639–46.PubMedCrossRefGoogle Scholar
  145. 145.
    Hassouna I, et al. Revisiting adult neurogenesis and the role of erythropoietin for neuronal and oligodendroglial differentiation in the hippocampus. Mol Psychiatry. 2016;21:1752–67.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    • Vinberg M, Weikop P, Olsen NV, Kessing LV, Miskowiak K. Effect of recombinant erythropoietin on inflammatory markers in patients with affective disorders: a randomized controlled study. Brain Behav Immun. 2016;57:53–7.Google Scholar
  147. 147.
    • Vinberg M, Miskowiak K, Hoejman P, Pedersen M, Kessing LV. The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomized controlled study. PLoS One. 2015;10.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018
corrected publication March/2018

Authors and Affiliations

  • Sabrina C. da Costa
    • 1
  • Rodrigo Machado-Vieira
    • 1
  • Jair C. Soares
    • 1
  1. 1.Department of Psychiatry and Behavioral Sciences, McGovern Medical SchoolUniversity of Texas Health Science Center at HoustonHoustonUSA

Personalised recommendations